Prognostic value of moderate or massive ascites in patients with advanced gastric cancer-Reference-Cited by-同舟云学术

Prognostic value of moderate or massive ascites in patients with advanced gastric cancer

Published:2024-01-22 Issue:3 Volume:27 Page:
ISSN:1792-1074
Container-title:Oncology Letters
language:
Short-container-title:Oncol Lett

Author:

Iwai Naoto¹,Ohara Tomoya¹,Okuda Takashi¹,Oka Kohei¹,Sakai Hiroaki¹,Kajiwara‑Kubota Mariko¹,Tsuji Toshifumi¹,Sakagami Junichi¹,Kagawa Keizo¹,Doi Toshifumi²,Inoue Ken²,Dohi Osamu²,Yoshida Naohisa²,Uchiyama Kazuhiko²,Ishikawa Takeshi²,Takagi Tomohisa²,Konishi Hideyuki²,Itoh Yoshito²

Affiliation:

1. Department of Gastroenterology and Hepatology, Fukuchiyama City Hospital, Fukchiyama, Kyoto 620‑8505, Japan

2. Department of Molecular Gastroenterology and Hepatology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto 602‑8566, Japan

Publisher

Spandidos Publications

Reference25 articles.

1. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries;Sung;CA Cancer J Clin,2021

2. Long-term survival after endoscopic resection for gastric cancer: Real-world evidence from a multicenter prospective cohort;Suzuki;Clin Gastroenterol Hepatol,2023

3. Long-term outcomes of laparoscopy-assisted distal gastrectomy with suprapancreatic nodal dissection for clinical stage I gastric cancer: A multicenter phase II trial (JCOG0703);Hiki;Gastric Cancer,2018

4. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): A randomised, open-label, phase 3 trial;Janjigian;Lancet,2021

5. Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): A randomised, multicentre, double-blind, placebo-controlled, phase 3 trial;Kang;Lancet Oncol,2022